Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
  • 260 views
  • 16 Sep, 2022
  • 31 locations
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants

Cohort 1: The primary objectives are: To evaluate the steady-state pharmacokinetics (PK) of Atazanavir (ATV) and Darunavir (DRV) and confirm the dose of Cobicistat-boosted

tenofovir
emtricitabine/tenofovir
tuberculosis
emtricitabine
atazanavir
  • 298 views
  • 19 Sep, 2022
  • 9 locations
The Late Presenter Treatment Optimisation Study (LAPTOP)

HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe

HIV Infection
hiv viral load
opportunistic infection
tenofovir
protease
  • 134 views
  • 16 May, 2022
  • 44 locations
Body Composition Sub-study of the D2EFT Trial

This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …

emtricitabine
lamivudine
antiretroviral agents
antiretroviral therapy
darunavir
  • 9 views
  • 21 Feb, 2022
  • 7 locations
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamic of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

Background Rivaroxaban and apixaban are blood thinners. People with HIV may need to take them to treat or prevent blood clots. The anti-HIV drug darunavir (DRV

blood test
body mass index
fasting
Accepts healthy volunteers
  • 6 views
  • 29 Jul, 2022
  • 1 location
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children Aged >=3 Years and Weighing >=15 kg to <25 kg

The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water.

  • 0 views
  • 20 Sep, 2022
  • 3 locations
HIV Pre-exposure Prophylaxis Implementation Study in South Korea

The primary objective of this study is to examine acceptability, patterns of use, rates of adherence, safety , and measured levels of drug when high risk men who have sex with men (MSM) are provided open-label tenofovir/emtricitabine (TDF/FTC) for PrEP in South Korea. Secondary objectives are 1) to evaluate HIV …

immune globulin
pre-exposure prophylaxis (prep)
tenofovir
HIV Vaccine
emtricitabine
  • 0 views
  • 26 Jan, 2021
Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge). (DORAge)

The HIV-infected population is aging due to the success of combination antiretroviral therapy, which prolongs survival, as well as the growing number of newly diagnosed cases in adults 50 years old and over. This real-life, observational and retrospective study aims to evaluate the virological efficacy, toxicity and tolerability of Doravirine-based …

Accepts healthy volunteers
  • 0 views
  • 24 Mar, 2022
Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir (NewHorizon)

The objectives of this data collection activity are to: Describe the baseline demographics, clinical and laboratory profile of patients who ever received darunavir (DRV) and/or

etravirine
Accepts healthy volunteers
darunavir
  • 23 views
  • 13 Apr, 2022
  • 4 locations
Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA) (PANNA)

Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy …

hiv antibodies
immune globulin
hiv antibody
haart
antibody test
  • 156 views
  • 16 Sep, 2022
  • 16 locations